- In late July 2026, Acadia Healthcare Company, Inc. reported second-quarter results showing sales of US$865.84 million and net income of US$10.93 million, alongside revised 2026 revenue guidance to a range of US$3.40 billion to US$3.45 billion.
- The update highlighted a contrast between flat quarterly revenue, a sharp earnings decline, and management’s increased full-year outlook as new facilities ramp up while legal and regulatory risks continue to weigh on profitability.
- We’ll now examine how Acadia’s higher full-year revenue guidance, despite weaker quarterly earnings, affects the company’s existing investment narrative.
The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Acadia Healthcare Company Investment Narrative Recap
To own Acadia, you have to believe that long term demand for behavioral health and the company’s expanding bed base will ultimately outweigh current profit pressure. The latest quarter does not change the key near term story: the main catalyst is still new facilities ramping into meaningful revenue, while the biggest risk remains legal and regulatory issues that are already dragging on earnings.
The most relevant update here is management’s decision to raise 2026 revenue guidance to US$3.40–US$3.45 billion despite flat quarterly sales and weaker profits. That guidance leans on new beds and facilities moving from start up losses toward breakeven and, eventually, contribution, even as Medicaid policy shifts and liability reserves offset some of the benefit in the near term.
Yet beneath the higher revenue outlook, investors should be aware that ongoing legal and regulatory investigations could still...
Read the full narrative on Acadia Healthcare Company (it's free!)
Acadia Healthcare Company's narrative projects $3.9 billion revenue and $189.9 million earnings by 2029.
Uncover how Acadia Healthcare Company's forecasts yield a $32.21 fair value, a 14% upside to its current price.
Exploring Other Perspectives
Before this update, the most optimistic analysts were banking on revenue reaching about US$4.0 billion and earnings of roughly US$262 million, a far rosier path than consensus and one that could be challenged or reinforced as new guidance interacts with persistent legal and facility level risks.
Explore 4 other fair value estimates on Acadia Healthcare Company - why the stock might be worth less than half the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Acadia Healthcare Company research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Acadia Healthcare Company research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Acadia Healthcare Company's overall financial health at a glance.
Searching For A Fresh Perspective?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com